Inflammatory Bowel Disease (IBD) is a chronic condition of the bowel affecting over 1.5 million people in the United States.

The recurrent nature of IBD makes affected patients ideal candidates for electronic patient reported outcome (e-PRO) monitoring that centers on enhanced symptom tracking and improved communication with care teams. HealthPROMISE is a prescribed mobile application that assesses the impact of e-PROs on improving patients’ quality of life (QoL).

In a pragmatic randomized trial at Mount Sinai Medical Center (MSMC), baseline e- PROs were measured using online questionnaires delivered through the app that assessed health literacy, disease severity, general health status, and demographic information. Patients using HealthPROMISE could update their e-PRO information and receive a disease summary. Patients could also communicate over the HealthPROMISE app and discuss results with providers.

At baseline, patients in the intervention arm reported a mean quality of life score of 30.3 ± 11.3. The last available follow-up QoL scores showed improvement among patients using HealthPROMISE to 25.3 ± 11.3 (p < 0.001). Patients engaging with HealthPROMISE reported more equitable participation in their care decision-making process, and showed improved health outcomes compared to patients not using HealthPROMISE.


Patients Enrolled

In the study, 162 were randomized
to the intervention group. 158 were randomized to the control group.


Quality of Care

Leads to positive health outcomes
as well as improvement in QoL


Active Patients

Who continue to frequently log into HealthPROMISE app and update their e-PROs.

Future Directions

HealthPROMISE has demonstrated a significant improvement in patients’ quality of care. Digital health interventions and remote monitoring can alleviate gaps in quality of care, increase patient engagement, and improve health outcomes. HealthPROMISE and these toolkits can be easily accessed by physicians using the RxUniverse platform.